Calliditas Therapeutics AB(NASDAQ : CALT)
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
Health Technology » Pharmaceuticals Major
|JNJ||Johnson & Johnson||-0.23%||177.11||0.7%||$1337.30m|
|MRK||Merck & Co., Inc.||-0.31%||90.89||0.7%||$1164.24m|
|LLY||Eli Lilly & Co.||-1.26%||320.15||1.1%||$1032.51m|
|BMY||Bristol-Myers Squibb Co.||-1.08%||76.17||1.0%||$997.00m|
|TPTX||Turning Point Therapeutics, Inc.||-0.09%||75.19||0.0%||$287.85m|
|HZNP||Horizon Therapeutics Plc||0.44%||80.11||5.4%||$162.52m|
|MRTX||Mirati Therapeutics, Inc.||5.38%||70.74||1.6%||$154.60m|
|ALNY||Alnylam Pharmaceuticals, Inc.||1.68%||148.30||8.1%||$142.88m|
|NVO||Novo Nordisk A/S||-0.77%||110.57||0.1%||$142.12m|
Calliditas Therapeutics AB clinical-stage biopharmaceutical company. It engages in the identification, development, and commercialization of novel treatments in orphan indications. The firm focuses on renal and hepatic diseases with significant unmet medical needs. It offers Nefecon, a proprietary, novel oral formulation of budesonide for the treatment of the autoimmune renal disease IgA nephropathy, or IgAN. The firm product TARPEYO is used to reduce proteinuria in adults with primary immunoglobulin. The company was founded by Mikael Bender and Bengt Ã…ke Julander on February 20, 2004 and is headquartered in Stockholm, Sweden.